Renal Outcomes in High-Risk Hypertensive Patients Treated With an Angiotensin-Converting Enzyme Inhibitor or a Calcium Channel Blocker vs a Diuretic

Authors:
  • SPSara Pressel
    Sara Pressel
  • CNChuke Nwachuku
    Chuke Nwachuku
  • JWJackson T. Wright
    Jackson T. Wright
  • PWPaul K. Whelton
    Paul K. Whelton
  • JBJoshua Barzilay
    Joshua Barzilay
  • JEJohn H. Eckfeldt
    John H. Eckfeldt
  • MFMichael Farber
    Michael Farber
  • MHMario Henriquez
    Mario Henriquez
  • NKNelson Kopyt
    Nelson Kopyt

Abstract
The prevalence of end-stage renal disease (ESRD) has doubled in the United States during the last decade and is expected to double again by the year 2010.1 Patients with ESRD experience substantial cardiovascular morbidity and mortality; in ad-dition, health costs related to ESRD exceed $12 billion annually.1 It is estimated that more than 10 million Americans have chronic kidney disease and are at high risk of developing ESRD.2 Therefore, therapeutic interventions that slow decline in renal function in patients with chronic kidney disease are important.3